Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
PLoS One ; 19(5): e0304479, 2024.
Article in English | MEDLINE | ID: mdl-38820514

ABSTRACT

Although dietary potassium restriction is an acceptable approach to hyperkalemia prevention, it may be insufficient for outpatients with chronic kidney disease (CKD). Most outpatients with CKD use community pharmacies owing to the free access scheme in Japan. The MieYaku-CKD project included a community pharmacist-led nutritional intervention for dietary potassium restriction, with the goal of determining its efficacy for patients' awareness of potassium restriction and serum potassium levels in outpatients with CKD. This was a five-community pharmacy multicenter prospective cohort study with an open-label, before-and-after comparison design. Eligible patients (n = 25) with an estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m2 received nutritional guidance from community pharmacists. The primary outcome was a change in serum potassium levels at 12 weeks post-intervention. The eligible patients' knowledge, awareness, and implementation of potassium restriction were evaluated using a questionnaire. The median value of serum potassium was significantly reduced from 4.7 mEq/L before to 4.4 mEq/L after the intervention [p < 0.001, 95% confidence interval (CI): 0.156-0.500], with no changes in eGFR (p = 0.563, 95% CI: -2.427-2.555) and blood urine nitrogen/serum creatinine ratio (p = 0.904, 95% CI: -1.793-1.214). The value of serum potassium had a tendency of attenuation from 5.3 to 4.6 mEq/L (p = 0.046, 95% CI: 0.272-1.114) in the eGFR < 30 mL/min/1.73 m2 group. A questionnaire revealed that after the intervention, knowledge and attitudes regarding dietary potassium restriction were much greater than before, suggesting that the decrease in serum potassium levels may be related to this nutritional guidance. Our findings indicate that implementing a dietary potassium restriction guidance program in community pharmacies is feasible and may result in lower serum potassium levels in outpatients with CKD.


Subject(s)
Glomerular Filtration Rate , Outpatients , Pharmacists , Potassium , Renal Insufficiency, Chronic , Humans , Female , Male , Renal Insufficiency, Chronic/diet therapy , Renal Insufficiency, Chronic/blood , Renal Insufficiency, Chronic/therapy , Prospective Studies , Aged , Potassium/blood , Middle Aged , Japan , Hyperkalemia/prevention & control , Hyperkalemia/blood , Hyperkalemia/diet therapy , Potassium, Dietary/administration & dosage , Aged, 80 and over
3.
Pediatr Nephrol ; 36(6): 1331-1346, 2021 06.
Article in English | MEDLINE | ID: mdl-33730284

ABSTRACT

Dyskalemias are often seen in children with chronic kidney disease (CKD). While hyperkalemia is common, with an increasing prevalence as glomerular filtration rate declines, hypokalemia may also occur, particularly in children with renal tubular disorders and those on intensive dialysis regimens. Dietary assessment and adjustment of potassium intake is critically important in children with CKD as hyperkalemia can be life-threatening. Manipulation of dietary potassium can be challenging as it may affect the intake of other nutrients and reduce palatability. The Pediatric Renal Nutrition Taskforce (PRNT), an international team of pediatric renal dietitians and pediatric nephrologists, has developed clinical practice recommendations (CPRs) for the dietary management of potassium in children with CKD stages 2-5 and on dialysis (CKD2-5D). We describe the assessment of dietary potassium intake, requirements for potassium in healthy children, and the dietary management of hypo- and hyperkalemia in children with CKD2-5D. Common potassium containing foods are described and approaches to adjusting potassium intake that can be incorporated into everyday practice discussed. Given the poor quality of evidence available, a Delphi survey was conducted to seek consensus from international experts. Statements with a low grade or those that are opinion-based must be carefully considered and adapted to individual patient needs, based on the clinical judgment of the treating physician and dietitian. These CPRs will be regularly audited and updated by the PRNT.


Subject(s)
Hyperkalemia , Potassium, Dietary , Renal Insufficiency, Chronic , Child , Humans , Hyperkalemia/diet therapy , Hyperkalemia/etiology , Hyperkalemia/prevention & control , Renal Dialysis/adverse effects , Renal Insufficiency, Chronic/complications , Renal Insufficiency, Chronic/diet therapy , Renal Insufficiency, Chronic/therapy
4.
Nephrol Dial Transplant ; 36(4): 681-688, 2021 03 29.
Article in English | MEDLINE | ID: mdl-33020805

ABSTRACT

BACKGROUND: Patients undergoing haemodialysis (HD) are often discouraged from eating fruits and vegetables because of fears of hyperkalaemia and undernutrition, yet evidence to support these claims is scarce. We here explore the association between adherence to a healthy plant-based diet with serum potassium, surrogates of nutritional status and attainment of energy/protein intake targets in HD patients. METHODS: We performed an observational single-centre study of stable patients undergoing HD with repeated dietary assessment every 3 months. Patients were provided with personalized nutritional counselling according to current guidelines. The diet was evaluated by 3-day food records and characterized by a healthy plant-based diet score (HPDS), which scores positively the intake of plant foods and negatively animal foods and sugar. The malnutrition inflammation score (MIS) and serum potassium were also assessed at each visit. We used mixed-effects models to evaluate the association of the HPDS with markers of nutritional status, serum potassium levels and attainment of energy/protein intake targets. RESULTS: After applying inclusion and exclusion criteria, a total of 150 patients contributing to 470 trimestral observations were included. Their mean age was 42 years [standard deviation (SD) 18] and 59% were women. In multivariable models, a higher HPDS was not associated with serum potassium levels or odds of hyperkalaemia {potassium >5.5 mEq/L; odds ratio [OR] 1.00 [95% confidence interval (CI) 0.94-1.07] per HPDS unit higher}. Patients with a higher HPDS did not differ in terms of energy intake [OR for consuming <30 kcal/kg day 1.05 (95% CI 0.97-1.13)] but were at risk of low protein intake [OR for consuming <1.1 g of protein/kg/day 1.11 (95% CI 1.04-1.19)]. A higher HPDS was associated with a lower MIS, indicating better nutritional status. CONCLUSIONS: In patients undergoing HD, adherence to a healthy plant-based diet was not associated with serum potassium, hyperkalaemia or differences in energy intake. Although these patients were less likely to reach daily protein intake targets, they appeared to associate with better nutritional status over time.


Subject(s)
Diet, Vegetarian , Energy Intake , Hyperkalemia/diet therapy , Malnutrition/prevention & control , Nutritional Status , Renal Dialysis/adverse effects , Adult , Female , Humans , Hyperkalemia/etiology , Hyperkalemia/pathology , Longitudinal Studies , Male , Malnutrition/etiology , Malnutrition/pathology , Middle Aged , Sweden/epidemiology , Young Adult
5.
Saudi J Kidney Dis Transpl ; 31(5): 1134-1139, 2020.
Article in English | MEDLINE | ID: mdl-33229781

ABSTRACT

Gordon syndrome involves hyperkalemia, acidosis, and severe hypertension (HTN) with hypercalciuria, low renin and aldosterone levels. It is commonly observed in children and adolescents. Such patients respond successfully to sodium restriction and thiazide diuretics. In this article, we present three cases of metabolic acidosis, hyperkalemia, and renal unresponsiveness to aldosterone (MeHandRU Syndrome). All three patients did not have HTN or hypercalciuria and demonstrated normal renin and aldosterone levels. These patients did not respond to thiazide-type diuretic therapy and salt restriction. Two males (aged 55- and 62-year) and a female patient (aged 68-year) presented to the clinic with unexplained hyperkalemia (5.9 mEq/L, 5.9 mEq/L and 6.2 mEq/L, respectively). On physical examination, blood pressure (BP) was found to be normal (<140/90 mm Hg). Over the counter potassium supplement, nonsteroidal anti-inflammatory drugs, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, potassium sparing diuretic use, as well as hyporeninemic hypoaldosteronism states such as diabetes mellitus were excluded. Plasma renin and aldosterone levels were normal. All three patients had low transtubular potassium gradient, despite high serum potassium levels. None of the patients reported a family history of hyperkalemia or kidney failure. All failed to demonstrate a response to hydrochlorothiazide and salt restriction. After careful consideration, strict low potassium diet (<2 g/day) was initiated in consultation with the dietician. Diuretic therapy was discontinued while BP remained within normal range (<140/90 mm Hg). At eight weeks, all three patients demonstrated normalization of potassium and correction of acidosis. At follow-up of six months, all patients are maintaining a normal potassium level. We suggest that potassium restriction can be successful in patients presenting with MeHandRU syndrome.


Subject(s)
Acidosis/diet therapy , Hyperkalemia/diet therapy , Pseudohypoaldosteronism/diet therapy , Acidosis/diagnosis , Acidosis/physiopathology , Aged , Aldosterone/blood , Female , Humans , Hyperkalemia/diagnosis , Hyperkalemia/physiopathology , Kidney/physiopathology , Male , Middle Aged , Potassium/blood , Pseudohypoaldosteronism/diagnosis , Pseudohypoaldosteronism/physiopathology
6.
J Ren Nutr ; 29(4): 350-353, 2019 07.
Article in English | MEDLINE | ID: mdl-30579674

ABSTRACT

Hyperkalemia and hyperphosphatemia are common metabolic disturbances in chronic kidney disease. Management may include instructions on a low-potassium or low-phosphorus diet, respectively. Low-phosphorus diet teaching includes information on phosphorus additives in addition to naturally occurring phosphorus food sources. Phosphorus additives are known to be more bioavailable compared with naturally occurring phosphorus. The concentration of phosphorus can also be much higher in processed foods compared with whole foods. Similar considerations may also be needed for dietary potassium teaching. The use of potassium additives in processed foods is growing, and when additives are used, the potassium concentration far exceeds naturally occurring potassium. Evidence also suggests, much like phosphate, potassium additives are more bioavailable than potassium found in whole foods. Clinicians and patients need to be aware of these changes in the food source to ensure potassium diet teaching is effective and safe.


Subject(s)
Food Additives/metabolism , Hyperkalemia/diet therapy , Potassium, Dietary/metabolism , Recommended Dietary Allowances , Food Additives/administration & dosage , Humans , Hyperkalemia/metabolism , Potassium, Dietary/administration & dosage
7.
G Ital Nefrol ; 35(5)2018 09.
Article in Italian | MEDLINE | ID: mdl-30234232

ABSTRACT

Hyperkalaemia is a common complication in patients with nondialysis Chronic Kidney Disease (CKD). It is associated with weakness, paralysis, arrhythmias and increased mortality. Higher serum potassium levels refractory to treatment is one of the most frequent reasons to initiate immediately renal replacement treatment in advanced stages of CKD. Hyperkalaemia is also indirectly associated with the progression of CKD; in fact higher serum potassium levels may lead to withdrawal of renin-angiotensin-system inhibiting drugs that currently represent the most effective tools to postpone ESRD. It is therefore essential to identify patients at higher risk of increase of serum K and to implement therapeutic interventions aimed at preventing and treating hyperkalaemia, such as diet modifications and greater use of diuretics and cation exchange resins. Sodium and calcium-polystyrenesulfonate (SPS) are the resins currently available in Italy. However, few studies showed that SPS is efficacious to reduce serum K and is associated with increased risk of severe adverse effects. Patiromer and ZS-9 represent a significant pharmacological progress in the treatment of hyperkalemia. Indeed, recent studies showed that these novel resins are efficient to reduce serum levels of K with minor occurrence of side effects than polystyrensulfonates. Furthermore, Patiromer, sodium free agent, might have a further advantage in CKD patients, reducing the salt intake in these patients. In addition, ZS-9, being fast-acting drug, might be used also in the treatment of acute hyperkalaemia.


Subject(s)
Cation Exchange Resins/therapeutic use , Diuretics/therapeutic use , Hyperkalemia/drug therapy , Renal Insufficiency, Chronic/complications , Cohort Studies , Combined Modality Therapy , Disease Progression , Drug Therapy, Combination , Gastrointestinal Diseases/chemically induced , Humans , Hyperkalemia/diet therapy , Hyperkalemia/etiology , Hyperkalemia/prevention & control , Kidney Failure, Chronic/prevention & control , Polymers/therapeutic use , Potassium, Dietary/administration & dosage , Renal Insufficiency, Chronic/therapy , Renal Replacement Therapy , Renin-Angiotensin System/drug effects , Retrospective Studies , Silicates/therapeutic use
8.
Nutrients ; 10(3)2018 Feb 25.
Article in English | MEDLINE | ID: mdl-29495340

ABSTRACT

Whereas the adequate intake of potassium is relatively high in healthy adults, i.e., 4.7 g per day, a dietary potassium restriction of usually less than 3 g per day is recommended in the management of patients with reduced kidney function, especially those who tend to develop hyperkalaemia including patients who are treated with angiotensin pathway modulators. Most potassium-rich foods are considered heart-healthy nutrients with high fibre, high anti-oxidant vitamins and high alkali content such as fresh fruits and vegetables; hence, the main challenge of dietary potassium management is to maintain high fibre intake and a low net fixed-acid load, because constipation and metabolic acidosis are per se major risk factors for hyperkalaemia. To achieve a careful reduction of dietary potassium load without a decrease in alkali or fibre intake, we recommend the implementation of certain pragmatic dietary interventions as follows: Improving knowledge and education about the type of foods with excess potassium (per serving or per unit of weight); identifying foods that are needed for healthy nutrition in renal patients; classification of foods based on their potassium content normalized per unit of dietary fibre; education about the use of cooking procedures (such as boiling) in order to achieve effective potassium reduction before eating; and attention to hidden sources of potassium, in particular additives in preserved foods and low-sodium salt substitutes. The present paper aims to review dietary potassium handling and gives information about practical approaches to limit potassium load in chronic kidney disease patients at risk of hyperkalaemia.


Subject(s)
Diet , Hyperkalemia/diet therapy , Kidney Failure, Chronic/diet therapy , Acidosis/diet therapy , Acidosis/etiology , Adult , Antioxidants/administration & dosage , Chronic Disease , Constipation/diet therapy , Constipation/etiology , Dietary Fiber/administration & dosage , Fruit , Humans , Hyperkalemia/complications , Kidney/metabolism , Kidney Failure, Chronic/complications , Micronutrients/administration & dosage , Potassium, Dietary/administration & dosage , Recommended Dietary Allowances , Renal Dialysis , Risk Factors , Sodium, Dietary/administration & dosage , Vegetables
10.
Am J Nephrol ; 40(6): 582-91, 2014.
Article in English | MEDLINE | ID: mdl-25613675

ABSTRACT

BACKGROUND: Chronic Kidney Disease (CKD) is associated with alterations in phosphorus excretion, and increases in fibroblast growth factor (FGF23) and parathyroid hormone (PTH). Plant protein-based phytate-bound phosphorus, is less bioavailable than that from animal sources. Our one-week study that was conducted previously showed that a nearly 100% plant protein-based diet benefits mineral metabolism in CKD; however, this diet may not be acceptable to patients. Here we hypothesize that a diet containing 70% protein from plants has similar efficacy and is tolerated by CKD patients. METHODS: Thirteen subjects with CKD 3-4 received an omnivorous diet containing 70% protein from plants for 4 weeks. The primary outcome was change in 24 h urine phosphorus. Secondary outcomes were changes in serum phosphorus, FGF23, PTH, urine sodium excretion, grip strength and fat free mass. Repeated measures analysis of variance (ANOVA) was used to test differences in parameters over the 4 weeks. RESULTS: Mean age of subjects was 54.8 years. Median eGFR was 26 (IQR 14.7) ml/min/1.73 m(2). Over the 4-week period, urine phosphorus significantly decreased by 215 ± 232 mg/day (p < 0.001). No significant changes in serum FGF23, phosphorus or PTH were noted. Urine sodium and titratable acid decreased significantly on the diet. Hand grip strength and fat-free mass did not change. There were two hyperkalemia events both 5.8 mEq/l, corrected by food substitutions. No other adverse events were observed. CONCLUSIONS: A 70% plant protein diet is safe, tolerated, and efficacious in lowering urine phosphorus excretion and may be an alternative to phosphate binders.


Subject(s)
Phosphorus/urine , Plant Proteins, Dietary/administration & dosage , Plant Proteins, Dietary/metabolism , Renal Insufficiency, Chronic/blood , Renal Insufficiency, Chronic/urine , Adult , Aged , Body Composition , Diet/adverse effects , Fibroblast Growth Factor-23 , Fibroblast Growth Factors/blood , Glomerular Filtration Rate , Hand Strength/physiology , Humans , Hyperkalemia/diet therapy , Hyperkalemia/etiology , Middle Aged , Parathyroid Hormone/blood , Phosphorus/blood , Sodium/urine
11.
J Vet Intern Med ; 24(3): 546-50, 2010.
Article in English | MEDLINE | ID: mdl-20337915

ABSTRACT

BACKGROUND: Hyperkalemia occurs in dogs with chronic kidney disease (CKD). OBJECTIVES: (1) To determine the incidence of hyperkalemia in dogs with CKD, (2) to determine the proportion of hyperkalemic dogs that required modification of dietary potassium intake, (3) to evaluate the response to dietary modification. METHODS: The hospital database was reviewed retrospectively to identify dogs with CKD and persistent (>5.3 mmol/L on at least 3 occasions) or severe (K > or = 6.5 mmol/L) hyperkalemia while consuming a therapeutic renal diet. Records of dogs with hyperkalemia that were prescribed a home-prepared, potassium-reduced diet were evaluated further. Response was evaluated by changes in body weight, BCS, and serum potassium concentration. RESULTS: One hundred and fifty-two dogs were diagnosed with CKD, of which 47% had > or =1 documented episode of hyperkalemia, 25% had > or = 3 episodes of hyperkalemia, and 16% had > or =1 episodes of severe hyperkalemia (K > 6.5 mmol/L). Twenty-six dogs (17.2%) with CKD and hyperkalemia were prescribed a potassium-reduced, home-prepared diet. The potassium concentration of all hyperkalemic dogs on therapeutic diets (potassium content, 1.6 +/- 0.23 g/1,000 kcal of metabolizable energy [ME]) was 6.5 +/- 0.5 mmol/L but decreased significantly to 5.1 +/- 0.5 mmol/L in 18 dogs available for follow-up in response to the dietary modification (0.91 +/- 0.14 g/1,000 kcal of ME, P < .001). Potassium concentration normalized in all but 1 dog. CONCLUSIONS AND CLINICAL IMPORTANCE: Hyperkalemia is a potential complication of CKD. In a subset of CKD dogs, hyperkalemia can be associated with commercial renal diets and could restrict use of these diets. Appropriately formulated, potassium-reduced, diets are an effective alternative to correct hyperkalemia.


Subject(s)
Animal Feed/analysis , Diet/veterinary , Hyperkalemia/veterinary , Kidney Failure, Chronic/veterinary , Potassium/chemistry , Animals , Dogs , Hyperkalemia/diet therapy , Hyperkalemia/etiology , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/diet therapy
12.
J Ren Nutr ; 20(2): 121-6, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19853475

ABSTRACT

OBJECTIVE: This study sought to evaluate the use of adult renal formulas in hyperkalemic infants with chronic kidney disease (CKD). DESIGN: This was a retrospective, single-center cohort study. SETTING: This study took place at the Department of Pediatric Nephrology, Dialysis, and Transplantation at Helen DeVos Children's Hospital (Grand Rapids, MI). PATIENTS: Seven hyperkalemic infants (mean age, 6.9 months) comprised the study population: 29% with stage 3 CKD, 29% with stage 4 CKD, and 42% with stage 5 CKD. INTERVENTION: Infants were empirically treated with adult renal formulas for an average duration of 9.6 months. Six of seven infants were started on breast milk or infant formula (Similac PM 60/40, Abbott Laboratories, Columbus, OH), but because of inadequate growth and hyperkalemia, were transitioned to adult renal formulas (Suplena, Abbott Laboratories, Columbus, OH; Nepro, Abbott Laboratories, Columbus, OH; and/or Renalcal, Nestle Nutrition, Minnetonka, MN). One infant received adult renal formula at birth. MAIN OUTCOME MEASURES: The outcome measures included amount of potassium delivered by infant and adult renal formulas, level of serum potassium, and anthropometric measurements adjusted for age and gender (z-scores). RESULTS: The transition from infant to adult renal formula resulted in a decrease in mean amount of potassium delivered by formula (from 2.6 to 1.0 mEq/kg/day, P < .001) and a decrease in mean serum potassium (from 5.1 to 4.0 mmol/L, P < .01). During treatment with adult renal formula, the infants demonstrated a significant increase in mean weight z-score (from -1.0 to 0.5, P < .01), height z-score (from -1.9 to -0.5, P < .01), and head-circumference z-score (from -1.5 to -1.0, P=.03). Adult renal formulas were well-tolerated. CONCLUSIONS: Hyperkalemic infants with CKD can be nutritionally managed on adult renal formula.


Subject(s)
Food, Formulated , Hyperkalemia/diet therapy , Kidney Diseases/diet therapy , Anthropometry , Anuria/diet therapy , Body Height , Chronic Disease , Cohort Studies , Food, Formulated/analysis , Humans , Hyperkalemia/etiology , Infant , Infant Formula/chemistry , Kidney Diseases/complications , Milk, Human , Polyuria/diet therapy , Potassium/analysis , Potassium/blood , Retrospective Studies , Weight Gain
13.
J Ren Nutr ; 19(6): 469-74, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19818299

ABSTRACT

BACKGROUND: Abnormal plasma potassium levels are not uncommon in peritoneal dialysis (PD) patients. Here, we implemented a continuous quality improvement (CQI) approach that mainly focused on dietary management to improve potassium control in PD patients. METHODS: All clinically stable patients who visited the PD clinic monthly were included in this study. A CQI team that included nephrologists, primary nurses, dietician, patients, and their family members was organized, and it monitored patients for 6 months. Patients were asked to provide their dialysis records and 3-day dietary records at each visit. Dialysis adequacy, including potassium and phosphorus removals, was checked before and after the implementation of CQI. Changes in dietary prescription, without altering dialysis prescriptions and potassium supplementation, were made monthly, according to patients' dietary information and blood potassium levels. RESULTS: In total, 84 patients (28 male and 56 female) were included in this study. At baseline, the prevalence of hyperkalemia and hypokalemia was 14.3% each. After the intervention, the prevalence of hyperkalemia dropped to 10.7% and 6% at 3 months and 6 months, respectively. The prevalence of hypokalemia dropped to 8.3% and 7.1% at 3 months and 6 months, respectively. CONCLUSIONS: Our data suggest that implementing CQI, with a focus on dietary intervention, could significantly reduce the prevalence of potassium abnormality in PD patients.


Subject(s)
Peritoneal Dialysis/methods , Potassium/blood , Total Quality Management/methods , Adolescent , Adult , Aged , Comorbidity , Diet Records , Female , Humans , Hyperkalemia/blood , Hyperkalemia/diet therapy , Hyperkalemia/epidemiology , Hypokalemia/blood , Hypokalemia/diet therapy , Hypokalemia/epidemiology , Kidney Diseases/epidemiology , Kidney Diseases/therapy , Male , Middle Aged , Prevalence , Young Adult
15.
Am J Nephrol ; 20(4): 268-72, 2000.
Article in English | MEDLINE | ID: mdl-10970978

ABSTRACT

BACKGROUND/AIMS: Angiotensin-converting enzyme inhibitors (ACEI) are the antihypertensives of choice in patients with chronic renal failure (CRF). ACEI by decreasing the synthesis of aldosterone, the main regulator of serum potassium, predispose to the development of hyperkalemia. Although hyperkalemia with administration of ACEI is uncommon in patients with a normal renal function, a preexisting abnormality in potassium hemostasis, as seen in patients with chronic renal failure, may increase the risk of hyperkalemia. METHOD: To determine the predictors of development of hyperkalemia (K >5.1 mEq/l) in patients on ACEI, we retrospectively reviewed medical records of 119 patients followed in our renal clinic. RESULTS: The mean age of the patients was 56 +/- (SD) 13 (range 20-84) years. Sixty-three percent were males, and 37% were females. Sixty-seven percent had a history of diabetes. Eighty five percent of the patients had CRF [creatinine clearance (CrCl) <80 ml/min]. The baseline serum Cr was 2.3 +/- 1.2 (range 0.6-6.9) mg/dl, and the CrCl was 50 +/- 27.5 ml/min. Of the 119 patients 46 (38.6%) developed hyperkalemia (mean K 5.68 +/- 0.3, range 5.2-6.7 mEq/l). Ninety-six percent of the patients who developed hyperkalemia had CRF, and 84% were diabetics. Pearson product-moment correlation revealed a significant positive correlation of hyperkalemia with Cr and a negative correlation of hyperkalemia with CrCl and HCO(3) (Cr: r = 0.42, p < 0.0001; CrCl: r = -0.34, p < 0.0001; HCO(3): r = -0.41, p < 0.0001). Multivariate logistic regression analysis revealed diabetes and serum creatinine to be the main predictors of hyperkalemia. In 31 patients hyperkalemia resolved either with a low-potassium (2 g/day) diet or with diet and a decrease in the dose of ACEI. In 15 patients ACEI had to be discontinued due to persistent hyperkalemia. CONCLUSIONS: We conclude that hyperkalemia is common in patients with CRF on ACEI. The majority of the patients who develop hyperkalemia on ACEI have CRF and diabetes. A large number of patients with CRF require discontinuation of ACEI due to hyperkalemia and are deprived of their renoprotective effects.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/adverse effects , Hyperkalemia/chemically induced , Adult , Aged , Aged, 80 and over , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Benzazepines/administration & dosage , Benzazepines/adverse effects , Diet , Dose-Response Relationship, Drug , Female , Humans , Hyperkalemia/diet therapy , Male , Middle Aged , Potassium/administration & dosage , Retrospective Studies
17.
Clin Exp Pharmacol Physiol ; 17(3): 191-5, 1990 Mar.
Article in English | MEDLINE | ID: mdl-2187635

ABSTRACT

1. Plasma potassium and chloride concentrations were raised and plasma renin activity, aldosterone, bicarbonate and arterial pH were reduced in two brothers with the syndrome of hypertension and hyperkalaemia with normal glomerular filtration rate (Gordon's syndrome), on unrestricted or moderately restricted sodium diets. 2. These abnormalities were corrected in both patients within 10 days of severe sodium restriction. 3. Pressor sensitivity to cold and angiotensin II decreased on low sodium diet, associated with a fall in blood pressure. 4. Increasing distal tubular sodium delivery by infusion of normal saline increased fractional excretion of potassium when aldosterone had been stimulated by severely restricted sodium diet, but not when aldosterone levels were low on unrestricted sodium diet. 5. These findings are consistent with excessive sodium reabsorption as the primary renal lesion in Gordon's syndrome, leading to volume expansion and suppression of renin and aldosterone. Severe dietary sodium restriction leading to volume contraction, by stimulating renin and aldosterone and promoting kaliuresis, corrects the abnormalities.


Subject(s)
Aldosterone/blood , Diet, Sodium-Restricted , Hyperkalemia/diet therapy , Hypertension/diet therapy , Renin/blood , Adult , Angiotensin II/blood , Animals , Family Health , Humans , Hyperkalemia/physiopathology , Hypertension/physiopathology , Male , Syndrome
19.
Postgrad Med J ; 62 Suppl 1: 179-82, 1986.
Article in English | MEDLINE | ID: mdl-3022272

ABSTRACT

Although converting-enzyme inhibition is of established value in the management of patients with severe chronic congestive heart failure, troublesome adverse reactions occur frequently during the course of treatment and may cause physicians to interrupt effective therapy. The three most common adverse reactions that are seen in patients with heart failure following treatment with captopril and enalapril (symptomatic hypotension, functional renal insufficiency, hyperkalaemia) are predictable consequences of interfering with the homeostatic functions of the renin-angiotensin system, which evolved millions of years ago to preserve life in sodium-depleted states. It is not surprising, therefore, that these untoward effects can be prevented or reversed by increasing the dietary intake of salt or reducing the dose of concomitantly administered diuretics; their occurrence rarely requires discontinuation of drug therapy. Recognition of this link between sodium balance and the adverse effects of converting-enzyme inhibition is important, because most patients with severe heart failure who experience such untoward reactions can nevertheless be expected to improve clinically during long-term therapy, if effective treatment is not interrupted.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors , Captopril/adverse effects , Enalapril/adverse effects , Heart Failure/drug therapy , Acute Kidney Injury/chemically induced , Acute Kidney Injury/diet therapy , Captopril/therapeutic use , Enalapril/therapeutic use , Heart Failure/enzymology , Humans , Hyperkalemia/chemically induced , Hyperkalemia/diet therapy , Hypotension/chemically induced , Hypotension/diet therapy , Sodium Chloride/therapeutic use
20.
J Lab Clin Med ; 103(3): 432-45, 1984 Mar.
Article in English | MEDLINE | ID: mdl-6366094

ABSTRACT

Hyperkalemia has been implicated in the pathogenesis of metabolic acidosis in chronic renal insufficiency because acidosis is ameliorated after administration of medications that correct hyperkalemia: mineralocorticoids, diuretics, intestinal K+-binding agents. However, the acidosis-ameliorating effect of these medications may be a consequence not of their ability to correct hyperkalemia, but of their ability to directly stimulate renal or intestinal excretion of acid. To investigate the specific effect of correcting hyperkalemia, balance studies were performed wherein hyperkalemia was corrected solely by restriction of dietary K+ in three patients with moderate chronic renal insufficiency (Ccreat 36, 44, and 58 ml/min/1.73 m2, respectively). Reduction of K+ intake was effected by substitution of Na+ for K+ in the electrolyte supplement to a whole-food diet of low K+ content. This maneuver resulted in correction of hyperkalemia and sustained amelioration of metabolic acidosis in each patient. Net acid excretion increased only transiently, and not enough to fully account for the magnitude of the increment in plasma [HCO3-], suggesting that an extrarenal mechanism of HCO3- input to the systemic circulation was the major factor that ameliorated the systemic acidosis. Evidence of an extrarenal mechanism was obtained only during the phase of decreasing plasma [K+]. Subsequently, during sustained normokalemia, the increased plasma [HCO3-] was maintained as a consequence of a sustained increase in total renal H+ secretion, evidenced by complete reabsorption of the increased filtered load of HCO3- and no reduction in net acid excretion from control values. These results indicate that in some patients with moderate chronic renal insufficiency, metabolic acidosis is ameliorated when hyperkalemia is corrected by restriction of dietary K+ (Na+ substitution) without otherwise changing diet composition and without administration of medication. Amelioration of the acidosis is predominantly effected by extrarenal mechanisms, and is sustained by an increase in the set point at which plasma [HCO3-] is regulated by the kidney.


Subject(s)
Acidosis, Renal Tubular/diet therapy , Hyperkalemia/complications , Kidney Failure, Chronic/complications , Aged , Aldosterone/urine , Ammonia/urine , Humans , Hydrogen-Ion Concentration , Hyperkalemia/blood , Hyperkalemia/diet therapy , Male , Middle Aged , Potassium/blood , Potassium/metabolism , Renin/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...